IBI362 Clinical Trials
6 recruitingDrug
Phase 34Phase 22
Showing 1–6 of 6 trials
Recruiting
Phase 3
Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity
ObesityOverweightHypertensive
Innovent Biologics (Suzhou) Co. Ltd.336 enrolled1 locationNCT07469800
Recruiting
Phase 3
A Study of IBI362 in Chinese Adolescents With Obesity or Overweight
Adolescents With Obesity or Overweight With Weight-Related Comorbidities
Innovent Biologics (Suzhou) Co. Ltd.180 enrolled1 locationNCT07255209
Recruiting
Phase 2
A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Metabolic dysfunction-associated steatohepatitis (MASH)
Innovent Biologics (Suzhou) Co. Ltd.165 enrolled1 locationNCT06937749
Recruiting
Phase 2
A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity
ObesityHeart Failure With Preserved Ejection Fraction (HFpEF)Heart Failure With Mildly Reduced Ejection Fraction
Innovent Biologics (Suzhou) Co. Ltd.141 enrolled1 locationNCT06862908
Recruiting
Phase 3
A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2
ObesitySleep ApneaObstructive
Innovent Biologics (Suzhou) Co. Ltd.260 enrolled1 locationNCT06931028
Recruiting
Phase 3
A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）
OverweightMetabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
Innovent Biologics (Suzhou) Co. Ltd.470 enrolled1 locationNCT06884293